摘要
慢性丙型肝炎(CHC)病毒感染和相关肝病仍然具有挑战性,世界各地的疾病负担仍然很大。慢性感染患者的总体治疗率“非常差”,在现实的临床环境中,聚乙二醇化干扰素(PEG-IFN)和利巴韦林(RBV)双重治疗的完成情况并不理想。第一代、第二代和下一代直接作用抗病毒药物(DAAS)的批准是丙型肝炎病毒(HCV)治疗方法在治疗CHC感染者方面的重大突破。这种固定剂量组合(FDC)或RBV的治疗方案已经证明了它们对不同HCV基因型的临床疗效,并且难以治疗特殊人群。我们继续看到新的泛基因型抗-HCV方案的发展,其持续病毒学应答(SVR;第12周或治疗结束时检测不到的病毒载量)非常高,对药物抵抗的高屏障,不良事件的发生率较低,与一些老的基于RBV的三重DAA疗法相比,药物相互作用更少。口服无干扰素DAAS似乎是治疗丙型肝炎的非常成功的战略治疗方法,并促使卫生政策制定者制定治疗优先顺序和政策,以降低丙型肝炎相关发病率和死亡率。本文全面综述了无干扰素抗-HCV方案,这些方案在一定程度上改变了丙型肝炎的治疗模式,并带来了一些额外的好处,以激励我们在不久的将来努力实现消除HCV的全球目标。
关键词: 无干扰素抗病毒药物、蛋白酶抑制剂、NS5a抑制剂、NS5b抑制剂、泛基因型治疗方案、DAA失败、HCV治疗。
Current Molecular Medicine
Title:All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C
Volume: 18 Issue: 7
关键词: 无干扰素抗病毒药物、蛋白酶抑制剂、NS5a抑制剂、NS5b抑制剂、泛基因型治疗方案、DAA失败、HCV治疗。
摘要: Chronic hepatitis C (CHC) virus infection and associated hepatic diseases are still challenging, and the disease burden remains significant around the world. Overall treatment rates for the chronically infected patients have been “dismally poor” and that treatment completion of dual-therapy— pegylated interferon (PEG-IFN) and ribavirin (RBV) is suboptimal in the real-world clinical settings. The approval of first, second and next-generation direct-acting antivirals (DAAs) represents a major breakthrough in hepatitis C virus (HCV) therapeutics to treat CHC infected individuals. Such therapeutic regimens in a fixed dose combination (FDC) or along with RBV have proven their clinical efficacy against different HCV genotypes, and harder-to-treat special populations. We continue to see the development of novel pan-genotypic anti-HCV regimens with very high sustained virologic response (SVR; undetectable viral load at week 12 or at the end of therapy) rates, high barrier to drug resistance, low frequency of adverse events, and fewer drug-drug interactions as compared to some older RBV based triple DAA therapies. Oral interferon-free DAAs seem highly successful strategic treatment approaches against hepatitis C and impulse health policy makers to establish the treatment priorties and policies to reduce the rate of hepatitis C-related morbidity and mortality. This review article comprehensively overviews interferon-free anti-HCV regimens, which have totally shifted the treatment paradigms for hepatitis C with some additional benefits to galvanize our efforts to achieve the global goal of HCV elimination in near future.
Export Options
About this article
Cite this article as:
All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C, Current Molecular Medicine 2018; 18 (7) . https://dx.doi.org/10.2174/1566524019666190104110439
DOI https://dx.doi.org/10.2174/1566524019666190104110439 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
RhoGEFs in Cell Motility: Novel Links Between Rgnef and Focal Adhesion Kinase
Current Molecular Medicine Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Current Drug Delivery Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer
Current Medicinal Chemistry Differences in Phosphorylated Histone H2AX Foci Formation and Removal of Cells Exposed to Low and High Linear Energy Transfer Radiation
Current Genomics Environmentally Sensitive Paramagnetic and Diamagnetic Contrast Agents for Nuclear Magnetic Resonance Imaging and Spectroscopy
Current Topics in Medicinal Chemistry Structure and Function of the Intercellular Junctions: Barrier of Paracellular Drug Delivery
Current Pharmaceutical Design Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy Research Progress of Axl Inhibitors
Current Topics in Medicinal Chemistry The Immunomodulation and Anti-Inflammatory Effects of Garlic Organosulfur Compounds in Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Radiation-Induced Stress Proteins - the Role of Heat Shock Proteins (HSP) in Anti- Tumor Responses
Current Medicinal Chemistry 2D QSAR and Virtual Screening based on Pyridopyrimidine Analogs of Epidermal Growth Factor Receptor Tyrosine Kinase
Current Computer-Aided Drug Design Clinical Considerations in Developing Dendritic Cell Vaccine Based Immunotherapy Protocols in Cancer
Current Molecular Medicine Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry Angiotensin-I Converting Enzyme Inhibitors as Potential Anti-Angiogenic Agents for Cancer Therapy
Current Cancer Drug Targets Could Growth Factor-Mediated Extracellular Matrix Deposition and Degradation Offer the Ground for Directed Pharmacological Targeting in Fibrosarcoma?
Current Medicinal Chemistry Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs
Current Medicinal Chemistry